Liquidia shares are trading lower. The company announced that the FDA granted tentative approval of YUTREPIA inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Portfolio Pulse from Benzinga Newsdesk
Liquidia shares are trading lower after the FDA granted tentative approval for YUTREPIA inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
August 19, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Liquidia shares are trading lower following the FDA's tentative approval of YUTREPIA inhalation powder for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
The tentative approval from the FDA indicates that while YUTREPIA has met the necessary requirements, it may still face hurdles before full approval. This uncertainty likely contributed to the decline in Liquidia's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100